EUVIMEDEUVIMED entdecken
Crossref

A Spanish survey on the use of the Aspergillus galactomannan antigen VirClia® Monotest chemiluminescent assay for the diagnosis of probable invasive aspergillosis

Andrea Medina, Eliseo Albert, Isabel Corrales, María Ángeles Clari, Ana Fernández-Cruz, David Navarro, This survey was endorsed by GEMICOMED (Medical Mycology Study Group from the Spanish Society of Microbiology and Infectious Diseases)

Enfermedades infecciosas y microbiologia clinica (English ed.) · 2026-11 · 44 (9) · 503266

DOI: 10.1016/j.eimce.2026.503266 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Enfermedades infecciosas y microbiologia clinica (English ed.), 2026-11. Verfasst von Andrea Medina und 6 weiteren Autor:innen. Beteiligte Einrichtung: Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain. Hauptthemen laut MEDLINE: Mannans, Antigens, Fungal, Luminescent Measurements, Invasive Pulmonary Aspergillosis. Die Arbeit nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: The Aspergillus Galactomannan Antigen VirClia® Monotest (Vircell S.L., Granada, Spain) has been implemented in many laboratories in Spain; however, its use has not been clinically validated for the management of invasive pulmonary aspergillosis (IPA). Here, we gathered information on current practices related to the use of the VirClia® GM assay in Spanish hospitals. METHODS: Spanish laboratory users of the VirClia® assay were invited to respond to a standardized questionnaire. RESULTS: The questionnaire was completed in full by 35 out of 54 (64.8%) invited microbiology laboratories and by 14 clinicians. In addition to serum and bronchoalveolar lavages, non-validated sample types such as bronchoaspirates and endotracheal aspirates are used by around 20% of laboratories. Most laboratories (94.3%) report qualitative results using a threshold for positivity of >0.2, irrespective of the sample type and the patient's underlying condition, which is considered by most responding clinicians as a mycological criterion for probable IPA. CONCLUSION: The current survey mainly reflects the heterogeneity in the use and interpretation of the VirClia® GM immunoassay, which, in the absence of clinically validated thresholds for probable IPA, introduces uncertainty and may lead to misinterpretations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MannansAntigens, FungalLuminescent MeasurementsInvasive Pulmonary AspergillosisAspergillusHumansGalactoseSpainSurveys and Questionnaires

Stichwörter der Autor:innen

Aspergilosis pulmonarEncuestaEnsayo Platelia® GMEnsayo VirClia® GMPlatelia® GM assayPulmonary aspergillosisSurveyVirClia® GM assay

Substanzen

GalactosegalactomannanMannansAntigens, Fungal

Autor:innen und Institutionen

  • Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain.
  • Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario Puerta de Hierro, IDIPHISA, Spain; Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.
  • Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain; CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain; Department of Microbiology School of…

Zitieren

APA

Medina, A., Albert, E., Corrales, I., Clari, M. Á., Fernández-Cruz, A., Navarro, D., & This survey was endorsed by GEMICOMED (Medical Mycology Study Group from the Spanish Society of Microbiology and Infectious Diseases) (2026). A Spanish survey on the use of the Aspergillus galactomannan antigen VirClia® Monotest chemiluminescent assay for the diagnosis of probable invasive aspergillosis. Enfermedades infecciosas y microbiologia clinica (English ed.), 44(9), 503266. https://doi.org/10.1016/j.eimce.2026.503266

Vancouver

Medina A, Albert E, Corrales I, Clari MÁ, Fernández-Cruz A, Navarro D, et al. A Spanish survey on the use of the Aspergillus galactomannan antigen VirClia® Monotest chemiluminescent assay for the diagnosis of probable invasive aspergillosis. Enfermedades infecciosas y microbiologia clinica (English ed.). 2026;44(9):503266. doi:10.1016/j.eimce.2026.503266

BibTeX
@article{Medina2026,
  author = {Medina, Andrea and Albert, Eliseo and Corrales, Isabel and Clari, María Ángeles and Fernández-Cruz, Ana and Navarro, David and This survey was endorsed by GEMICOMED (Medical Mycology Study Group from the Spanish Society of Microbiology and Infectious Diseases), This survey was endorsed by GEMICOMED (Medical Mycology Study Group from the Spanish Society of Microbiology and Infectious Diseases)},
  title = {A Spanish survey on the use of the Aspergillus galactomannan antigen VirClia® Monotest chemiluminescent assay for the diagnosis of probable invasive aspergillosis},
  journal = {Enfermedades infecciosas y microbiologia clinica (English ed.)},
  year = {2026},
  volume = {44},
  number = {9},
  pages = {503266},
  doi = {10.1016/j.eimce.2026.503266}
}
Kostenlos starten →